Stocks / NYSE / Gelesis Holdings Inc.

Gelesis Holdings Inc.

Our Opinion

Gelesis Holdings Inc. is on the Cruelty-Free Investing usage of animals list because they undertake pre-clinical studies on animals to examine the safety profile of their medications.

Supporting Evidence:

The company stated in the following press release that they use animals for drug testing.

“Gelesis, along with collaborators at Humanitas University in Milan, Italy, also examined how Gel-B supports growth of A. muciniphila in an animal model.” Read the following article

Company Description

Gelesis Holdings, Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. It also offers PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, the company develops GS200 for weight loss in prediabetes and type 2 diabetes; and GS500 for functional constipation. Further, it develops pre-clinical product GS300 for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis. Gelesis Holdings, Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

Company Website: